RANDOMIZED TRIAL OF IRINOTECAN AND CETUXIMAB (IC) VERSUS IRINOTECAN, CETUXIMAB AND RAMUCIRUMAB (ICR) AS 2ND LINE THERAPY OF ADVANCED COLORECTAL CANCER (CRC) FOLLOWING OXALIPLATIN AND BEVACIZUMB BASED THERAPY: RESULT OF E7208
Howard S. Hochster, Paul J. Catalano, Peter J. O’Dwyer, Edith P. Mitchell, Deirdre Jill Cohen, Bryan Andrew Faller, Jeremy S. Kortmansky, Sheetal Mehta Kircher, Jill Lacy, Heinz-Josef Lenz, Udit N. Verma, Al Bowen Benson, ECOG-ACRIN
Rutger-Cancer Institute, New Brunswick, NJ; Dana-Farber Cancer Institute, Boston, MA
University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
Meeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3504 Citation: J Clin Oncol 36, 2018 (suppl; abstr 3504) Authors: Howard S. Hochster, Paul J. Catalano, Peter J. O’Dwyer, Edith P. Mitchell, Deirdre Jill Cohen, Bryan Andrew Faller, Jeremy S. Kortmansky, Sheetal Mehta Kircher, Jill Lacy, Heinz-Josef Lenz, Udit...